Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study.
Bavaro DF, De Vito A, Pasculli G, Bouba Y, Magnasco L, Pincino R, Saladini F, Lattanzio R, Corsini R, Arima S, Zazzi M, Incardona F, Rossetti B, Bezenchek A, Vanni B, Di Biagio A. Bavaro DF, et al. Among authors: di biagio a. J Med Virol. 2022 Aug;94(8):3890-3899. doi: 10.1002/jmv.27754. Epub 2022 Apr 9. J Med Virol. 2022. PMID: 35355293 Free PMC article.
Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Rosso R, Nasi M, Di Biagio A, Repetto E, Dentone C, Pinti M, Nemes E, Ferraresi R, Mussini C, Esposito R, Viscoli C, Cossarizza A. Rosso R, et al. Among authors: di biagio a. Pediatr Infect Dis J. 2008 Jan;27(1):17-21. doi: 10.1097/INF.0b013e31814689be. Pediatr Infect Dis J. 2008. PMID: 18162932 Clinical Trial.
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).
Di Vincenzo P, Rusconi S, Adorni F, Vitiello P, Maggiolo F, Francisci D, Di Biagio A, Monno L, Antinori A, Boeri E, Punzi G, Perno CF, Callegaro A, Bruzzone B, Zazzi M; Antiretroviral Resistance Cohort Analysis (ARCA) Collaborative Group. Di Vincenzo P, et al. Among authors: di biagio a. HIV Med. 2010 Sep;11(8):530-4. doi: 10.1111/j.1468-1293.2009.00819.x. Epub 2010 Mar 8. HIV Med. 2010. PMID: 20236364 Free article.
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Prosperi MC, et al. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. J Med Virol. 2010. PMID: 20981785
444 results